Article info
PDFBook club
When breath becomes air
- Correspondence to Dr Gashirai K Mbizvo, Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK; gashirai.mbizvo{at}ed.ac.uk
Citation
When breath becomes air
Publication history
- Received May 13, 2017
- Accepted May 21, 2017
- First published June 29, 2017.
Online issue publication
November 24, 2017
Article Versions
- Previous version (24 November 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis
- Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
- Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
- Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer
- A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B
- Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis
- The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
- Mechanisms of resistance to EGFR-targeted drugs: lung cancer
- Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
- Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer